1. RVU120, a small molecule inhibitor of CDK8/19 kinases, enhances rituximab-driven NK cells-mediated cytotoxicity both in vitro and in vivo. (October 2022) Authors: Białopiotrowicz-Data, E.; Dziedzic, K.; Podkalicka, P.; Grycuk, K.; Gołas, A.; Dolata, I.; Chmielewski, S.; Pilch, Z.; Nowis, D.; Juszczyński, P.; Rzymski, T. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SEL120–34A, a specific, potent and orally bioavailable inhibitor of CDK8, targets STAT-dependent gene transcription in leukemia and lymphoma models. (December 2016) Authors: Zylkiewicz, E.; Rzymski, T.; Mikula, M.; Dreas, A.; Wiklik, K.; Wrobel, A.; Golas, A.; Dolata, I.; Wojcik, K.; Masiejczyk, M.; Statkiewicz, M.; Kuklinska, U.; Goryca, K.; Grochowsk, A.; Cabaj, A.; Bialas, A.; Mikulski, M.; Windak, R.; Ostrowski, J.; Brzozka, K. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗